The Living Guidelines: Renin-Angiotensin-Aldosterone System Blockers: Aldosterone Blockade Polling Results for CLASS I Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class I Guidelines
1. Use of aldosterone blockade in post MI patients without significant renal dysfunction or hyperkalemia is recommended in patients who are already receiving therapeutic doses of an ACE inhibitor and beta blocker, have an LVEF of less than or equal to 40%, and have either diabetes or HF. (Class I Level of Evidence: A)  AHA / ACC 2007 PCI Guidelines Class I Recommendation 1 for Renin-Angiotensin-Aldosterone System Blockers: Aldosterone Blockade should be CLASS I CLASS IIa CLASS IIb CLASS III